[December 4 – 5, 2013]
DNDi Ten Year Anniversary Event
Institut Pasteur, Paris, France
In 2013 DNDi celebrated its 10th anniversary and organized a series of events, of which the last one took place on 5 December 2013 in Paris, France, at the Institut Pasteur.
This specific scientific event “Best Science for the Most Neglected – Where Do We Stand 10 Years On?” was co-hosted by DNDi’s founding partners, Institut Pasteur and MSF, in collaboration with PLOS. Over 400 participants, from the field of research and development for neglected diseases, including international scientists, product developers, policy-makers, and civil society organizations, participated to the conference, which explored the scientific aspects of the past decade of innovation for neglected diseases carried out by various innovative initiatives, including DNDi.
10 Years of Portfolio Building for Neglected Diseases: A PDP Experience
Main Progress and Key Challenges in Drug Discovery for the Infectious Diseases in the Past Decade
Breakthroughs and Challenges in Clinical Development
The Future of Research on Neglected Diseases
Closing Remarks by Mr Djillali Annane, Conseiller Recherche et Eduction de la Ministre des Affaires Sociales
Closing Remarks by Prof Marcel Tanner, Chair DNDi Board of Directors, Director Swiss Tropical and Public Health Institute
Scientific Symposium, 4 December 2013
New Tools for Research on Kinetoplastid Diseases
4 December Programme & Speaker Biographies [PDF]
The day before, 140 participants were present at the kick-off event, the scientific symposium “New Tools for Research on Kinetoplastid Diseases”.
Please click here for more information on the kick-off event.
PLOS DNDi Collection
As part of a collaborative initiative, PLOS and DNDi launched a special Collection—PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D (Research and Development).
DNDi Model Report
To mark its 10 year anniversary, DNDi issued a report that explores the lessons learned from a decade of research and development (R&D) of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model.